Biological therapies for myasthenia gravis. (4th March 2023)

• Record Type: Journal Article
• Authors: Uzawa, Akiyuki; Utsugisawa, Kimiaki
• Is Part Of: Expert opinion on biological therapy. Volume 23:Number 3(2023)
• Page Start: 253
• Page End: 260
• Publication Date: 2023-03-04
• Subjects: anti-B cell drug -- biological drug -- complement inhibitors -- IL-6 receptor inhibitor -- neonatal Fc receptor inhibitor -- refractory; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2023.2184257
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: Recently, treatments for myasthenia gravis (MG) have progressed significantly. Symptoms of some patients with refractory MG are not relieved by conventional therapies, and such patients might benefit from novel biological treatments that are being developed. Areas covered: We review several novel biological therapies for MG, such as complement inhibitors, neonatal Fc receptor inhibitors, anti-B cell drugs, and IL-6 receptor inhibitors. We also report the modes of action, efficacy, safety, and tolerability of these drugs. Expert opinion: Several biological therapies have been developed for MG, and these biologics are promising agents for treating refractory MG. Establishing biomarkers and accumulating evidence of therapeutic response is required to provide the most appropriate biological treatment for each patient.